Phase I first-in-human trial of modified-release formulations of methylphenidate (including HLD 200) versus immediate-release methylphenidate in adult volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
Price : $35 *
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus First in man; Pharmacokinetics
- 19 Apr 2017 According to an Ironshore Pharmaceutical and Development media release, clinical data will be presented at the 6th World Congress on ADHD (Attention Deficit / Hyperactivity Disorder) 2017.
- 27 Jun 2013 New trial record
- 25 Jun 2013 Positive results reported in a Highland Therapeutics media release.